Marc H.  Hedrick net worth and biography

Marc Hedrick Biography and Net Worth

Marc H. Hedrick, M.D. Dr. Hedrick joined the Company in October 2002 as Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014 he was appointed as Chief Executive Officer. Dr. Hedrick has served as a member of our Board since joining the Company in October 2002. Previously, Dr. Hedrick served in a number of executive leadership positions, including as President and Chief Executive Officer of Cytori Therapeutics, President and Chief Executive Officer of StemSource, and Chief Scientific Officer and Medical Director of Macropore Biosurgery. Dr. Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career, Dr. Hedrick was Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles. Dr. Hedrick’s academic research received both NIH funding as well as private and public capitalization and was widely acknowledged through scientific publications and the media. Dr. Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from The UCLA Anderson School of Management and is a trained general, vascular and plastic surgeon. We believe Dr. Hedrick’s qualifications to serve on our Board include his executive, financial, governance and operational leadership experience in medical and pharmaceutical product development. Furthermore, Dr. Hedrick has first-hand experience as a physician, practicing general, vascular and craniofacial surgery.

What is Marc H. Hedrick's net worth?

The estimated net worth of Marc H. Hedrick is at least $306.85 as of November 20th, 2023. Dr. Hedrick owns 170 shares of Plus Therapeutics stock worth more than $307 as of March 28th. This net worth estimate does not reflect any other assets that Dr. Hedrick may own. Additionally, Dr. Hedrick receives an annual salary of $945,340.00 as CEO at Plus Therapeutics. Learn More about Marc H. Hedrick's net worth.

How old is Marc H. Hedrick?

Dr. Hedrick is currently 61 years old. There are 4 older executives and no younger executives at Plus Therapeutics. Learn More on Marc H. Hedrick's age.

What is Marc H. Hedrick's salary?

As the CEO of Plus Therapeutics, Inc., Dr. Hedrick earns $945,340.00 per year. Learn More on Marc H. Hedrick's salary.

How do I contact Marc H. Hedrick?

The corporate mailing address for Dr. Hedrick and other Plus Therapeutics executives is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. Plus Therapeutics can also be reached via phone at 737-255-7194 and via email at [email protected]. Learn More on Marc H. Hedrick's contact information.

Has Marc H. Hedrick been buying or selling shares of Plus Therapeutics?

Marc H. Hedrick has not been actively trading shares of Plus Therapeutics within the last three months. Learn More on Marc H. Hedrick's trading history.

Who are Plus Therapeutics' active insiders?

Plus Therapeutics' insider roster includes Marc Hedrick (CEO), Robert Lenk (Director), Greg Petersen (Director), and Andrew Sims (CFO). Learn More on Plus Therapeutics' active insiders.

Are insiders buying or selling shares of Plus Therapeutics?

In the last year, Plus Therapeutics insiders bought shares 9 times. They purchased a total of 43,888 shares worth more than $77,812.49. In the last year, insiders at the sold shares 1 times. They sold a total of 2,068 shares worth more than $4,053.28. The most recent insider tranaction occured on November, 20th when CEO Marc H Hedrick sold 2,068 shares worth more than $4,053.28. Insiders at Plus Therapeutics own 2.3% of the company. Learn More about insider trades at Plus Therapeutics.

Information on this page was last updated on 11/20/2023.

Marc H. Hedrick Insider Trading History at Plus Therapeutics

See Full Table

Marc H. Hedrick Buying and Selling Activity at Plus Therapeutics

This chart shows Marc H. Hedrick's buying and selling at Plus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Plus Therapeutics Company Overview

Plus Therapeutics logo
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $1.81
Low: $1.76
High: $1.85

50 Day Range

MA: $1.94
Low: $1.63
High: $2.23

2 Week Range

Now: $1.81
Low: $0.97
High: $5.10

Volume

41,388 shs

Average Volume

32,433 shs

Market Capitalization

$7.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6